Standard

Natural infection as a blueprint for rational HIV vaccine design. / van Haaren, Marlies M.; van den Kerkhof, Tom L. G. M.; van Gils, Marit J.

In: Human vaccines & immunotherapeutics, Vol. 13, No. 1, 2017, p. 229-236.

Research output: Contribution to journalReview articleAcademicpeer-review

Harvard

APA

Vancouver

van Haaren MM, van den Kerkhof TLGM, van Gils MJ. Natural infection as a blueprint for rational HIV vaccine design. Human vaccines & immunotherapeutics. 2017;13(1):229-236. Epub 2016. doi: 10.1080/21645515.2016.1232785

Author

BibTeX

@article{7ada7140c4d2440f998a106deca5d6a6,
title = "Natural infection as a blueprint for rational HIV vaccine design",
abstract = "So far, the development of a human immunodeficiency virus (HIV) vaccine has been unsuccessful. However, recent progress in the field of broadly neutralizing antibodies (bNAbs) has reinvigorated the search for an HIV vaccine. bNAbs develop in a minority of HIV infected individuals and passive transfer of these bNAbs to non-human primates provides protection from HIV infection. Studies in a number of HIV infected individuals on bNAb maturation alongside viral evolution and escape have shed light on the features important for bNAb elicitation. Here we review the observations from these studies, and how they influence the rational design of HIV vaccines",
author = "{van Haaren}, {Marlies M.} and {van den Kerkhof}, {Tom L. G. M.} and {van Gils}, {Marit J.}",
year = "2017",
doi = "10.1080/21645515.2016.1232785",
language = "English",
volume = "13",
pages = "229--236",
journal = "Human vaccines & immunotherapeutics",
issn = "2164-5515",
publisher = "Landes Bioscience",
number = "1",

}

RIS

TY - JOUR

T1 - Natural infection as a blueprint for rational HIV vaccine design

AU - van Haaren, Marlies M.

AU - van den Kerkhof, Tom L. G. M.

AU - van Gils, Marit J.

PY - 2017

Y1 - 2017

N2 - So far, the development of a human immunodeficiency virus (HIV) vaccine has been unsuccessful. However, recent progress in the field of broadly neutralizing antibodies (bNAbs) has reinvigorated the search for an HIV vaccine. bNAbs develop in a minority of HIV infected individuals and passive transfer of these bNAbs to non-human primates provides protection from HIV infection. Studies in a number of HIV infected individuals on bNAb maturation alongside viral evolution and escape have shed light on the features important for bNAb elicitation. Here we review the observations from these studies, and how they influence the rational design of HIV vaccines

AB - So far, the development of a human immunodeficiency virus (HIV) vaccine has been unsuccessful. However, recent progress in the field of broadly neutralizing antibodies (bNAbs) has reinvigorated the search for an HIV vaccine. bNAbs develop in a minority of HIV infected individuals and passive transfer of these bNAbs to non-human primates provides protection from HIV infection. Studies in a number of HIV infected individuals on bNAb maturation alongside viral evolution and escape have shed light on the features important for bNAb elicitation. Here we review the observations from these studies, and how they influence the rational design of HIV vaccines

U2 - 10.1080/21645515.2016.1232785

DO - 10.1080/21645515.2016.1232785

M3 - Review article

C2 - 27649455

VL - 13

SP - 229

EP - 236

JO - Human vaccines & immunotherapeutics

JF - Human vaccines & immunotherapeutics

SN - 2164-5515

IS - 1

ER -

ID: 2987603